Interaction of morphine with a new alpha2-adrenoceptor agonist in mice. 2010

Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
Programa de Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil. rtsudo@farmaco.ufrj.br

Finding new chemicals or adjuvants with analgesic effects in the central nervous system is clinically relevant due to the limited number of drugs with these properties. Here, we present PT-31, which is chemically related to 3-benzyl-imidazolidine, with an analgesic profile that results from alpha(2)-adrenoceptor activation. Intraperitoneal administration of PT-31 dose-dependently produced antinociception in the hot plate test, and interacted synergistically with morphine. This effect was completely reversed by yohimbine, a non-selective antagonist of alpha(2)-adrenoceptors, and by BRL 44408, a selective alpha(2A)-adrenoceptor antagonist. The combination of morphine and PT-31 produced greater antinociceptive activity than either alone, and isobolographic analysis revealed a synergistic interaction between these compounds. Docking results confirm the high affinity of the PT-31 ligand at the alpha(2A)-adrenoceptor. CONCLUSIONS This study introduces a new analgesic compound (PT-31) that acts via alpha(2A)-adrenoceptor activation. A significant increase in analgesia was observed when co-administered with morphine. PT-31 is an interesting new substance for pain therapy.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic

Related Publications

Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
July 2009, The Journal of pharmacy and pharmacology,
Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
October 2003, Archives of physiology and biochemistry,
Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
August 2004, European journal of pharmacology,
Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
January 2004, CNS drug reviews,
Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
December 2009, Naunyn-Schmiedeberg's archives of pharmacology,
Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
August 2000, Current opinion in anaesthesiology,
Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
September 2000, Anesthesiology,
Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
November 1997, Neuroscience letters,
Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
February 2004, Anesthesiology,
Roberto T Sudo, and Jorge A Calasans-Maia, and Suely L Galdino, and Maria C A Lima, and Gisele Zapata-Sudo, and Marcelo Z Hernandes, and Ivan R Pitta
December 1999, General pharmacology,
Copied contents to your clipboard!